View source for Ramatroban

{{short description|Chemical compound}}
{{Infobox drug
| IUPAC_name = 3-((3''R'')-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9''H''-carbazol-9-yl)propanoic acid
| image = Ramatroban.svg
| alt = 
| caption =

<!-- Clinical data -->
| pronounce =
| tradename = Baynas
| Drugs.com = {{Drugs.com|international|ramatroban}}
| MedlinePlus = 
| pregnancy_category = 
| routes_of_administration = Oral ([[Tablet (pharmacy)|tablets]])
| legal_status = Rx-only <small>([[Japan|JP]])</small>

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 
| duration_of_action= 
| excretion =

<!-- Identifiers -->
| CAS_number = 116649-85-5
| ATCvet = 
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 123879
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P1ALI72U6C
| IUPHAR_ligand = 1910
| ChEMBL = 361812
| ChemSpiderID = 110413
| KEGG = D01128

<!-- Chemical data -->
| chemical_formula  = 
| C=21 | H=21 | F=1 | N=2 | O=4 | S=1
| smiles = C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
| StdInChI = 1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
| StdInChIKey = LDXDSHIEDAPSSA-OAHLLOKOSA-N
}}

'''Ramatroban''' ([[International Nonproprietary Name|INN]]; also known as '''BAY u3405''')<ref name="PubChem">{{cite web |title=Ramatroban (compound) |url=https://pubchem.ncbi.nlm.nih.gov/compound/Ramatroban |website=PubChem |publisher=National Center for Biotechnology Information |access-date=22 June 2019}}</ref> is a [[thromboxane receptor antagonist]].<ref name="pmid12649388">{{cite journal | vauthors = Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, Bacon KB | display-authors = 6 | title = An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 305 | issue = 1 | pages = 347–352 | date = April 2003 | pmid = 12649388 | doi = 10.1124/jpet.102.046748 | name-list-style = vanc | s2cid = 10016709 }}</ref>  It is also a [[DP2 receptor|DP<sub>2</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="pmid18837743">{{cite journal | vauthors = Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, Beri R, Sargent C, Schmidt JA, Lang-Loidolt D, Heinemann A | display-authors = 6 | title = A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils | journal = European Journal of Clinical Investigation | volume = 38 | issue = 9 | pages = 663–671 | date = September 2008 | pmid = 18837743 | doi = 10.1111/j.1365-2362.2008.01989.x | name-list-style = vanc | doi-access = free }}</ref>

Ramatroban is indicated for the treatment of [[coronary artery disease]].<ref name="pmid2260140">{{cite journal | vauthors = Fiedler VB, Seuter F, Perzborn E | title = Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease | journal = Stroke | volume = 21 | issue = 12 Suppl | pages = IV149–IV151 | date = December 1990 | pmid = 2260140 | url = http://pt.wkhealth.com/pt/re/stroke/pdfhandler.00007670-199012001-00037.pdf }}</ref> It has also been used for the treatment of [[asthma]].<ref name="pmid8950952">{{cite journal | vauthors = Endo S, Akiyama K | title = [Thromboxane A2 receptor antagonist in asthma therapy] | language = ja | journal = Nihon Rinsho. Japanese Journal of Clinical Medicine | volume = 54 | issue = 11 | pages = 3045–3048 | date = November 1996 | pmid = 8950952 }}</ref>  

It has been suggested that ramatroban, by modulating [[DP2 receptor|DP<sub>2</sub> receptor]], can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced by [[SARS-Cov-2]].{{Cn|date=October 2021}} Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of [[COVID-19]] disease, although no clinical trial has yet been conducted.<ref name="pmid32696108">{{cite journal | vauthors = Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN | title = Pharmaco-Immunomodulatory Therapy in COVID-19 | journal = Drugs | volume = 80 | issue = 13 | pages = 1267–1292 | date = September 2020 | pmid = 32696108 | pmc = 7372203 | doi = 10.1007/s40265-020-01367-z }}</ref>

Ramatroban was developed by the German pharmaceutical company [[Bayer|Bayer AG]] and is co-marketed in [[Japan]] by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name '''Baynas'''.

== References ==
{{Reflist|2}}

== External links ==
* {{in lang|ja}} [http://www.nippon-shinyaku.co.jp/assets/files/pdfs/medicine/product/ha/baynas/interview_baynas_t.pdf Baynas Tablets Prescribing Information]

{{Antithrombotics}}
{{Asthma and copd rx}}
{{Prostanoidergics}}

[[Category:Antiplatelet drugs]]
[[Category:Beta-Amino acids]]
[[Category:Sulfonamides]]
[[Category:4-Fluorophenyl compounds]]
[[Category:Tetrahydrocarbazoles]]